Cornerstone Capital Management Holdings LLC. raised its holdings in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 1.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 283,200 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.62% of Amphastar Pharmaceuticals worth $5,060,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Alps Advisors Inc. lifted its position in Amphastar Pharmaceuticals by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 39,250 shares of the company’s stock valued at $701,000 after purchasing an additional 101 shares during the period. Municipal Employees Retirement System of Michigan lifted its position in Amphastar Pharmaceuticals by 2.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock valued at $151,000 after purchasing an additional 230 shares during the period. The Manufacturers Life Insurance Company lifted its position in Amphastar Pharmaceuticals by 1.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after purchasing an additional 312 shares during the period. Victory Capital Management Inc. lifted its position in Amphastar Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after purchasing an additional 842 shares during the period. Finally, Thrivent Financial For Lutherans lifted its position in Amphastar Pharmaceuticals by 7.2% during the 2nd quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock valued at $386,000 after purchasing an additional 1,460 shares during the period. Institutional investors own 44.14% of the company’s stock.

In related news, Director Stephen B. Shohet sold 7,862 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $18.34, for a total transaction of $144,189.08. Following the completion of the sale, the director now directly owns 31,978 shares of the company’s stock, valued at approximately $586,476.52. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Stephen B. Shohet sold 7,866 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $18.87, for a total value of $148,431.42. Following the sale, the director now directly owns 31,982 shares of the company’s stock, valued at $603,500.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 202,917 shares of company stock valued at $3,753,601. 11.10% of the stock is owned by company insiders.

Shares of Amphastar Pharmaceuticals Inc (NASDAQ AMPH) opened at $19.30 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. The company has a market capitalization of $883.19, a PE ratio of 128.07 and a beta of 1.69. Amphastar Pharmaceuticals Inc has a 52 week low of $12.05 and a 52 week high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.05. The company had revenue of $57.90 million during the quarter, compared to analysts’ expectations of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. Amphastar Pharmaceuticals’s revenue was down 9.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.14 EPS. sell-side analysts predict that Amphastar Pharmaceuticals Inc will post -0.03 earnings per share for the current year.

A number of brokerages have recently commented on AMPH. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $19.00 price target on shares of Amphastar Pharmaceuticals in a research note on Sunday, September 17th. Needham & Company LLC upped their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, December 1st. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group set a $19.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, Raymond James Financial cut Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price target for the company. in a research note on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $20.86.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/cornerstone-capital-management-holdings-llc-grows-holdings-in-amphastar-pharmaceuticals-inc-amph/1767140.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.